Could one of the scientists here confirm please that this new approved indication was not a primary endpoint?
https://clinicaltrials.gov/ct2/show/NCT03057951

I have for so long wondered if Resverlogix shouldn't be behaving a lot more assertively and be lobbying the FDA for approval of Apabetalone for Congested Heart Failure, a BoM secondary end-point that we acheived with extreme success and safety.